文献速递呼吸衰竭与机械通气重症综合管理与镇静镇痛

衰弱对澳大利亚和新西兰重症监护病房收治的COVID-19肺炎与非COVID-19肺炎患者临床结局的影响:一项回顾性登记数据分析

Impact of frailty on clinical outcomes in patients with and without COVID-19 pneumonitis admitted to intensive care units in Australia and New Zealand: a retrospective registry data analysis.
PubMed 文献 · Crit Care · 2022-10-03
一句话结论在澳大利亚和新西兰153个ICU中,衰弱是病毒性肺炎(含COVID-19)患者死亡的独立危险因素,且对COVID-19与非COVID-19患者的影响相似。

这项多中心回顾性队列研究基于澳大利亚和新西兰重症监护学会成人患者数据库,纳入2020年1月1日至2021年12月31日期间153个ICU收治的≥16岁、有病毒性肺炎或急性呼吸窘迫综合征诊断编码且有临床衰弱量表(CFS)评分的患者,共4620例,其中3077例(66.6%)为COVID-19。COVID-19患者较非COVID-19患者更年轻(中位57.0岁 vs 66.1岁,p<0.001)且衰弱程度更低(中位CFS 3 vs 4,p<0.001)。两组院内死亡率相似(14.7% vs 14.9%,p=0.82)。调整澳大利亚和新西兰死亡风险评分及性别后,衰弱评分升高与院内死亡率相关,但COVID-19与非COVID-19患者中衰弱效应相似(OR=1.29,95%CI 1.19-1.41 vs OR=1.24,95%CI 1.11-1.37)。作者结论认为衰弱是死亡的独立危险因素,但其对结局的影响在COVID-19与其他原因病毒性肺炎之间相似。

要点

  • 在153个ICU的4620例病毒性肺炎患者中,COVID-19患者3077例(66.6%),其院内死亡率为14.7%,非COVID-19患者为14.9%,两组相似(p=0.82)。
  • COVID-19患者较非COVID-19患者更年轻(中位57.0岁 vs 66.1岁,p<0.001)且衰弱程度更低(中位CFS 3 vs 4,p<0.001)。
  • 衰弱单独预测死亡区分存活与死亡的能力仅为中等,COVID-19与非COVID-19患者相似(AUROC 0.68 vs 0.66,p=0.42)。
  • 调整澳大利亚和新西兰死亡风险评分及性别后,衰弱评分升高与院内死亡率相关,COVID-19患者OR=1.29(95%CI 1.19-1.41),非COVID-19患者OR=1.24(95%CI 1.11-1.37)。
  • 衰弱对结局的影响在COVID-19与其他原因病毒性肺炎之间相似(OR=1.29 vs OR=1.24)。

适用人群与场景

  • 年龄≥16岁、入住澳大利亚和新西兰153个ICU、有病毒性肺炎或急性呼吸窘迫综合征诊断编码且有临床衰弱量表(CFS)评分的患者,纳入时间为2020年1月1日至2021年12月31日。

诊断标准与关键阈值

  • 使用临床衰弱量表(CFS)评估衰弱,评分越高表示越衰弱。

研究设计与关键结果

  • 研究类型为多中心回顾性队列研究,使用澳大利亚和新西兰重症监护学会成人患者数据库,纳入153个ICU的4620例患者,其中3077例(66.6%)为COVID-19。
  • COVID-19患者较非COVID-19患者更年轻(中位[IQR] 57.0[44.7-68.3]岁 vs 66.1[52.0-76.2]岁;p<0.001)且衰弱程度更低(中位[IQR] CFS 3[2-4] vs 4[3-5];p<0.001)。
  • 总体院内死亡率在COVID-19与非COVID-19患者间相似(14.7% vs 14.9%;p=0.82)。
  • 衰弱单独预测死亡区分存活与死亡的能力仅为中等,但COVID-19与非COVID-19患者相似(AUROC 0.68 vs 0.66;p=0.42)。
  • 调整澳大利亚和新西兰死亡风险评分及性别后,衰弱评分升高与院内死亡率相关,但COVID-19与非COVID-19患者中衰弱效应相似(OR=1.29;95%CI 1.19-1.41 vs OR=1.24;95%CI 1.11-1.37)。

证据类型、等级与局限

  • 证据类型:多中心回顾性队列研究。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者结论认为衰弱是死亡的独立危险因素,但其对结局的影响在COVID-19与其他原因病毒性肺炎之间相似。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: It is unclear if the impact of frailty on mortality differs between patients with viral pneumonitis due to COVID-19 or other causes. We aimed to determine if a difference exists between patients with and without COVID-19 pneumonitis.

METHODS: This multicentre, retrospective, cohort study using the Australian and New Zealand Intensive Care Society Adult Patient Database included patients aged ≥ 16 years admitted to 153 ICUs between 01/012020 and 12/31/2021 with admission diagnostic codes for viral pneumonia or acute respiratory distress syndrome, and Clinical Frailty Scale (CFS). The primary outcome was hospital mortality.

RESULTS: A total of 4620 patients were studied, and 3077 (66.6%) had COVID-19. The patients with COVID-19 were younger (median [IQR] 57.0 [44.7-68.3] vs. 66.1 [52.0-76.2]; p < 0.001) and less frail (median [IQR] CFS 3 [2-4] vs. 4 [3-5]; p < 0.001) than non-COVID-19 patients. The overall hospital mortality was similar between the patients with and without COVID-19 (14.7% vs. 14.9%; p = 0.82). Frailty alone as a predictor of mortality showed only moderate discrimination in differentiating survivors from those who died but was similar between patients with and without COVID-19 (AUROC 0.68 vs. 0.66; p = 0.42). Increasing frailty scores were associated with hospital mortality, after adjusting for Australian and New Zealand Risk of Death score and sex. However, the effect of frailty was similar in patients with and without COVID-19 (OR = 1.29; 95% CI: 1.19-1.41 vs. OR = 1.24; 95% CI: 1.11-1.37).

CONCLUSION: The presence of frailty was an independent risk factor for mortality. However, the impact of frailty on outcomes was similar in COVID-19 patients compared to other causes of viral pneumonitis.

来源:Crit Care,查看原文。版权归原作者所有。

参考来源

  1. Subramaniam A, Shekar K, Anstey C, et al. Impact of frailty on clinical outcomes in patients with and without COVID-19 pneumonitis admitted to intensive care units in Australia and New Zealand: a retrospective registry data analysis. Crit Care. 2022. PMID: 36192763. doi:10.1186/s13054-022-04177-9

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。